Alto Neuroscience (NYSE:ANRO) CFO Sells $621,125.92 in Stock

Alto Neuroscience, Inc. (NYSE:ANRO) CFO Nicholas Smith sold 24,056 shares of Alto Neuroscience stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $25.82, for a total value of $621,125.92. Following the transaction, the chief financial officer owned 24,060 shares of the company’s stock, valued at $621,229.20. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Nicholas Conrad Smith also recently made the following trade(s):

• On Tuesday, September 29th, Nicholas Smith sold 110,830 shares of Alto Neuroscience stock. The shares were sold at an average price of $26.58, for a total value of $2,945,861.40.

Alto Neuroscience Stock Performance

ANRO opened at $24.77 on Friday. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. Alto Neuroscience, Inc. has a 12-month low of $4.71 and a 12-month high of $37.48. The business has a 50 day moving average of $31.09 and a 200-day moving average of $26.14. The stock has a market cap of $972.05 million, a price-to-earnings ratio of -10.24 and a beta of 1.31.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08. On average, equities research analysts expect that Alto Neuroscience, Inc. will post -2.68 earnings per share for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP raised its stake in Alto Neuroscience by 18.6% in the 2nd quarter. Wellington Management Group LLP now owns 70,913 shares of the company’s stock worth $1,871,000 after purchasing an additional 11,114 shares in the last quarter. AWM Investment Company Inc. acquired a new position in shares of Alto Neuroscience during the 2nd quarter worth approximately $2,111,000. Bank of New York Mellon Corp acquired a new position in shares of Alto Neuroscience during the 2nd quarter worth approximately $2,014,000. GK Wealth Management LLC bought a new position in shares of Alto Neuroscience during the second quarter worth approximately $226,000. Finally, Perceptive Advisors LLC increased its holdings in shares of Alto Neuroscience by 12.6% during the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after purchasing an additional 225,500 shares during the period.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Zacks Research upgraded shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. Wedbush increased their price target on shares of Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. HC Wainwright raised their price objective on shares of Alto Neuroscience from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. BTIG Research boosted their price objective on Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.25.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and neurological disorders. The company seeks to use neuroscience, digital health tools and biological and behavioral biomarkers to identify patient subgroups that may respond to specific treatments.

Alto’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions. Its development programs are designed to address limitations of conventional psychiatric treatment by matching therapies to patient characteristics and measuring treatment response through objective data.